Orexo's share is listed on NasdaqOMX Stockholm, Sweden (ORX), and is available as American Depository Receipts on OTCQX market in the US (OXROY).
Share price
Name
0.00
0 SEK (0%)
HH:MM CET • 20YY-MM-DD
APRIL 22, 2021
Invitation to presentation of the Q1 Interim Report
Latest presentations
Find your topic of interest
Analyst reports
Investment thesis
Latest CEO Comments
APRIL 29, 2021
"ZUBSOLV® demand will contribute to a solid foundation for future growth"
Read the latest CEO comments from Nikolaj Sørensen
News flow
Press Releases and News
Orexo’s Partner Gesynta Pharma announces progresses in phase II study of OX-MPI and submits IND with FDA
Orexo continues to strengthen ZUBSOLV´s patent portfolio with two new patents
Invitation to presentation of Orexo´s Q1 Interim Report, on April 29 at 2 pm CET
Orexo continues to strengthen IP rights for ZUBSOLV®
Key financial figures
Group net revenue
621 MSEK
Last Twelve Months, Q220-Q121
Group EBITDA
-44 MSEK
Last Twelve Months, Q220-Q121
US Pharma segment EBIT
322 MSEK
Last Twelve Months, Q220-Q121
Cash position
726 MSEK
Q121
